samedan logo
 
 
spacer
home > pmps > spring 2003 > generic medicine - what's in it for the health service?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Generic Medicine - What's in it for the Health Service?

While pharma faces its toughest challenge yet from generics competition, Bluepharma's newly opened Research & Development Services Laboratories will boost the flow of new products through its pharma clients' commercial pipeline while the company continues to expand its contract manufacturing services business.

In March 2003 Bluepharma, a contract production services organisation based in Coimbra, Portugal, a spin-off from Bayer, launched its brand new laboratories offering product research and development services.

This event took place in the same week that Portugal's Government introduced a system of reimbursement by referential pricing (see Generic Medicine - What's in it for the Health Service, page 76), which will pose one of the toughest challenges ever for the nation's pharma industry entering the market for generic medicines.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Patricia Lobo, Editor of PMPS

Dr Luis Filipe Pereira, Minister for Health at Inauguration of Bluepharma's New R&D Laboratories

Dr Paulo Barradas, CEO of Bluepharma

Dr Isolina Mesquita, Director of Operations & Plant Manager

Professor Sergio Simoes, Head of Bluepharma's R&D Laboratory


spacer
Dr Patricia Lobo
spacer
spacer
spacer
Dr Luis Filipe Pereira
spacer
spacer
spacer
Dr Paulo Barradas
spacer
spacer
spacer
Dr Isolina Mesquita
spacer
spacer
spacer
Professor Sergio Simoes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera launches UniSpray, its unidose system primarily for systemic-acting drug administration

Nemera has a proven track record in developing and manufacturing complex Ear Nose and Throat solutions. In line with clear growing market interest in unidose system coupled with promising advantages that nasal route could offer, Nemera is thrilled to extend its portfolio by launching its unidose system, UniSpray, for systemic-acting drug administration to face emergency and crisis.
More info >>

White Papers

Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring

Dycem

A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement